According to AAOIFI Shariah screening standards, Prostatype Genomics AB (PROGEN.ST) is currently classified as Not Halal (Non-Compliant). This is based on both business activity and financial ratio screening.

Identified interest income is 15.2% of Prostatype Genomics AB's total income. AAOIFI standards require non-permissible income to be below 5%.

PROGEN.ST is screened using AAOIFI Standard No. 21, which involves two checks: business activity screening (ensuring the company's core business is permissible in Islam) and financial ratio screening (checking debt, interest income, and cash ratios against defined thresholds). AAOIFI is the most widely recognized standard for Islamic finance.

Prostatype Genomics AB's compliance status is reviewed whenever new financial data becomes available, typically after quarterly or annual earnings reports. Market cap changes can also affect financial ratio screening results. Mizaan refreshes screening data periodically to reflect the latest filings.

Watch PROGEN.ST free with a Mizaan account. Watched stocks are re-checked weekly, and any verdict change is dated in the verdict history on this page. Premium members also get an alert when it changes.

Approximately 15.15% of dividend income from Prostatype Genomics AB comes from non-permissible sources such as interest income. Many investors purify that share by donating it to charity; scholars differ on the details, so check with one you trust.

Yes, Zakat is generally due on stock holdings. The calculation depends on your school of thought (madhab) and whether you hold shares for trading or long-term investment. Use Mizaan's Zakat calculator to compute your obligation based on your specific madhab and holding intent.